- US11633476utility2023Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Methods of Use Thereof0 cites
- US11634511utility2023Processes for the Preparation of Sugammadex0 cites
- US11590237utility2023Pharmaceutical Formulation Comprising Incretin-insulin Conjugates0 cites
- US11591315utility2023Substituted Pyrazole-pyrimidines, Variants Thereof, and Uses Therefore0 cites
- US11585817utility2023Scoring Methods for Anti-pd Therapy Eligibility and Compositions for Performing Same0 cites
- US11587463utility2023Patient Training Device for Use with a Safety Syringe Injector0 cites
- US11566051utility2023Stabilized RSV F Proteins and Uses Thereof0 cites
- US11566057utility2023Long-acting Co-agonists of the Glucagon and GLP-1 Receptors0 cites
- US11566065utility2023Antibody Neutralizing Human Respiratory Syncytial Virus0 cites
- US11568001utility2023Radial Map Data Visualization0 cites
- US11554172utility2023Phosphonate Linkers and Their Use to Facilitate Cellular Retention of Compounds0 cites
- US11542279utility2023Solid Forms of Ceftolozane and Processes for Preparing0 cites
- US11542505utility2023Substituted RIG-I Agonists: Compositions and Methods Thereof0 cites
← PreviousPage 10 of 10